Safety pharmacology and risk assessment

Fundamental and Clinical Pharmacology

Volumn 16, Issue 3, 2002, Pages 175-182

  Kinter, Lewis B ^a   Valentin, Jean Pierre ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Arrhythmias; Biomarkers; Risk assessment; Safety pharmacology

Indexed keywords

ANTIARRHYTHMIC AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT;

ANESTHESIA; DEPOLARIZATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HUMAN; MEASUREMENT; NONHUMAN; PR INTERVAL; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TORSADE DES POINTES; VALIDATION PROCESS;

ANIMALS; ARRHYTHMIA; BIOLOGICAL MARKERS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; ELECTROCARDIOGRAPHY; HUMANS; PHARMACOLOGY, CLINICAL; RESEARCH DESIGN; RISK ASSESSMENT; SAFETY;

EID: 0036425817     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2002.00104.x     Document Type: Review

References (25)

1. Marchall E. Volunteer's death prompts review. Science (2001) 292 2226-2227.
2. Morgan D.G., Kelvin A.S., Kinter L.B. et al. The application of toxicokinetic data to dosage selection in toxicology studies. Toxicologic Pathol. (1994) 22 112-123.
3. Anon. Guidance for Industry: M3 Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. Federal Register (62 FR 62922) (1997) 25 November.
4. Zbinden G. Neglect of function and obsession with structure in toxicity testing, in: Proceedings, 9th International Congress of Pharmacology, Vol. 1. Macmillan, New York, 1984, pp. 43-49.
5. Williams P.D. The role of pharmacological profiling in safety assessment. Regul. Toxicol. & Pharmacol. (1990) 12 238.
6. Kinter L.B., Gossett K.A., Kerns W.D. Status of safety pharmacology in the pharmaceutical industry, 1993. Drug Dev Res. (1994) 32 208-216.
7. Kinter L.B., Murphy D.J., Mann W.A. et al. Major organ systems toxicology: An integrated approach to pharmacodynamic safety assessment in animals, in: Williams P. & Hottendorf G.H. (eds), Toxicology Testing and Evaluation, Vol. 2 of Sipes G., McQueen C.A. & Gandolfi A.J. (eds), Comprehensive Toxicology, Elsevier Science, London, 1997, pp. 155-168.
8. Anon. ICH S7A: Safety Pharmacology Studies for Human Pharmaceuticals. CPMP/ICH/539/00, (16 November 2000), http://www.ifpma.org/ich5s.html.
9. Anon. Notes on Applications for Approval to Manufacture (Import) New Drugs, MHW, Tokyo, Japan, 1975.
10. Anon. Japanese Guidelines for Nonclinical Studies of Drugs Manual 1995. Yakuji Nippo Limited, Tokyo, Japan, 1995
11. Anon. Guidelines for General Pharmacology Studies, MHW, Tokyo, Japan, 1991.
12. Kinter L.B., Dixon L.W. Safety pharmacology program for pharmaceuticals. Drug Dev. Res. (1995) 35 179-182.
13. Kurata M., Kanai K., Mizuguchi K. et al. Trends in safety pharmacology in the U.S. and Europe. J. Toxicol. Sci. (1997) 22 237-248.
14. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Therapeutics (2001) 69 89-95.
15. Tomaselli G.F., Beuckelmann D.J., Calkins H.G. et al. Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation (1994) 90 2534-2539.
16. Thomas S.H.L. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React. Toxicol. Rev. (1994) 13 77-102.
17. De Ponti F., Poluzzi E., Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: A call for consensus. Eur. J. Clin. Pharmacol. (2001) 57 185-209.
18. Moss A.J., The Q.T. interval and torsade de pointes. Drug Safety (1999) 21 5-10.
19. Haverkamp W., Breithart G., Camm A.J. et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Cardiovasc. Res. (2000) 47 219-233.
20. Committee for Proprietary Medicinal Products (EU). Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Products (1997). http://www.emea.eu.int/pdfs/human/swp/098696en.pdf.
21. Therapeutic Products Directorate Guidance Document (Canada). Assessment of the QT Prolongation Potential of Non-antiarrhythmic Drugs (2001). http://www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/guidmain.html.
22. Anon. ICH Guideline on Safety Pharmacology Studies for Assessing the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (S7B), Step 2 (2002).
23. Hammond T.G., Carlsson L., Davis A.S. et al. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey. Cardiovasc. Res. (2001) 49 741-750.
24. Igarashi T., Nakane S., Kitagawa T. Predictability of clinical adverse reactions of drugs by general pharmacology studies. J. Toxicol. Sci. (1995) 20 77-92.
25. Anon. ICHS6: Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals (July 1997). http://www.ifpma.org/ich5s.html.